| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.27▼ | 2.26▼ | 2.25▼ | 2.22▲ | 2.19▲ |
| MA10 | 2.25▼ | 2.23▲ | 2.25▼ | 2.17▲ | 2.25▼ |
| MA20 | 2.23▲ | 2.23▲ | 2.22▲ | 2.19▲ | 2.91▼ |
| MA50 | 2.20▲ | 2.17▲ | 2.15▲ | 2.33▼ | 2.95▼ |
| MA100 | 2.15▲ | 2.22▲ | 2.21▲ | 3.24▼ | 1.98▲ |
| MA200 | 2.27▼ | 2.22▲ | 2.37▼ | 3.19▼ | 107.37▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.001▲ | 0.001▲ | 0.027▲ | -0.112▼ |
| RSI | 52.935▲ | 53.913▲ | 54.455▲ | 50.231▲ | 43.263▼ |
| STOCH | 77.917 | 64.167 | 60.000 | 71.409 | 21.289 |
| WILL %R | -45.455 | -41.667 | -41.667 | -19.355▲ | -80.805▼ |
| CCI | 17.778 | 26.492 | 25.447 | 99.837 | -27.381 |
|
Wednesday, May 14, 2025 08:19 AM
Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses ...
|
|
Tuesday, May 13, 2025 09:10 PM
This is looking to be a pivotal year for ENSC, with the company’s lead product, PF614, which is a potential “next generation” analgesic to treat pain relief and is abuse resistant ...
|
|
Tuesday, May 13, 2025 09:10 PM
Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/07/25 | 2.20 | 2.29 | 2.17 | 2.24 | 40,507 |
| 30/06/25 | 2.28 | 2.28 | 2.20 | 2.23 | 20,902 |
| 27/06/25 | 2.28 | 2.28 | 2.16 | 2.24 | 34,849 |
| 26/06/25 | 2.18 | 2.24 | 2.15 | 2.22 | 24,908 |
| 25/06/25 | 2.16 | 2.20 | 2.15 | 2.18 | 16,718 |
| 24/06/25 | 2.12 | 2.30 | 2.12 | 2.20 | 88,453 |
| 23/06/25 | 2.03 | 2.149 | 2.03 | 2.13 | 49,180 |
| 20/06/25 | 2.07 | 2.1199 | 2.02 | 2.02 | 43,338 |
| 18/06/25 | 2.10 | 2.14 | 2.07 | 2.13 | 30,388 |
| 17/06/25 | 2.09 | 2.14 | 2.05 | 2.08 | 14,161 |
|
|
||||
|
|
||||
|
|